Christopher Starr
Oprichter bij MONOPAR THERAPEUTICS INC.
Vermogen: 47 190 $ op 30-04-2024
Actieve functies van Christopher Starr
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MONOPAR THERAPEUTICS INC. | Voorzitter | 01-12-2014 | - |
Oprichter | 01-12-2014 | - | |
Independent Dir/Board Member | 01-12-2014 | - | |
THIOGENESIS THERAPEUTICS, CORP. | Voorzitter | 31-03-2022 | - |
Independent Dir/Board Member | 31-03-2022 | - | |
Raptor Discoveries, Inc. | Algemeen Directeur | 08-09-2005 | - |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Directeur/Bestuurslid | 01-06-2016 | - |
Voorzitter | 01-04-2016 | 01-06-2016 |
Loopbaan van Christopher Starr
Eerdere bekende functies van Christopher Starr
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
RAPTOR PHARMACEUTICAL CORP | Directeur/Bestuurslid | 24-11-2010 | 25-10-2016 |
Algemeen Directeur | 01-10-2009 | 01-01-2015 | |
Oprichter | 29-09-2009 | 25-10-2016 | |
Independent Dir/Board Member | 29-09-2009 | 25-10-2016 | |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Directeur/Bestuurslid | 01-01-2005 | 01-10-2016 |
Algemeen Directeur | 01-01-2005 | 01-01-2014 | |
Oprichter | 01-01-2005 | 01-10-2016 | |
President | 01-01-2005 | 01-01-2014 | |
BIOMARIN PHARMACEUTICAL INC. | Hoofd Techniek/Wetenschap/O&O | - | 01-01-2006 |
Oprichter | 01-01-1997 | 01-01-2006 | |
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Hoofd Techniek/Wetenschap/O&O | 01-01-1991 | 01-01-1998 |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - | - |
░░░ ░░░░░░░░ ░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van Christopher Starr
SUNY Upstate Medical University | Doctorate Degree |
Syracuse University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 12 |
Canada | 2 |
Operationeel
Founder | 4 |
Director/Board Member | 3 |
Chief Executive Officer | 3 |
Sectoraal
Health Technology | 7 |
Consumer Services | 3 |
Government | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
MONOPAR THERAPEUTICS INC. | Health Technology |
THIOGENESIS THERAPEUTICS, CORP. | Finance |
Bedrijven in privébezit | 7 |
---|---|
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Health Technology |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
The National Research Council
The National Research Council Miscellaneous Commercial ServicesCommercial Services The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC. | Commercial Services |
Horizon Pharmaceutical LLC
Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Discoveries, Inc. | |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
- Beurs
- Insiders
- Christopher Starr
- Ervaring